AbbVie Submits Regulatory Applications to FDA and EMA for Rinvoq in Crohn ' s Disease

NORTH CHICAGO, Ill., July 27, 2022. AbbVie today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (Rinvoq 45 mg [induction dose] and...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials